# Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg

> **NCT00648778** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 53 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Loxapine Succinate Capsules 25 mg
- **DRUG:** Loxitane® Capsules 25 mg

## Key facts

- **NCT ID:** NCT00648778
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2003-02
- **Final completion:** 2003-02
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648778, "Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00648778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*